Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | March 25, 2024 | March 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERO THERAPEUTICS HOLDINGS, INC.
Report date March 25, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-03-24 | Direct | 112,500 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 112,500 · Balance 112,500 F1: The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2024 Filed Mar 28, 2024 01:28 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001213900-24-026823 · ownership.xml · derivative · entry 1 Rapaport Robyn · CIK 0002010809 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2034-03-24 F1 · derivative.exercise_date: The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.